Hydrogen sulfide ameliorates isoflurane-induced cognitive impairment in mice: Implication of caspase-3 activation

Dan Chen¹, Yi-Ling Fang¹, Ling-Ling Zhang¹, Xiao-Yin Niu¹, Xiao-Ru Sun¹, Xiao-Zhen Niu¹, Xuan Zhao¹, Cheng Li¹,²*

¹Department of Anesthesiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, P.R. China, ²Anesthesia and Brain Research Institute, Tongji University School of Medicine, Shanghai, P.R. China

*For correspondence: Email: chengli0903@163.com; Tel: +86-13214171828

Sent for review: 23 Feb 2020
Revised accepted: 26 Mar 2020

Abstract

Purpose: Isoflurane could induce cognitive impairment and activate caspase-3. However, the mechanism of action is unclear and target interventions are unavailable. The present study examined the potential protective function of hydrogen sulfide (H₂S) against isoflurane-induced cognitive impairment.

Methods: Effects of NaHS (5 mg/kg) on cognitive impairment induced by isoflurane (1.4% for 2 h) were assessed using a fear-conditioning test in a group of 8-month old mice. H4 human neuroglioma cells, which were transfected with upregulated human amyloid precursor protein were treated for 3 or 6 h with 2% isoflurane, in the presence of 100-μM NaHS in the mice. A group of mice treated with normal saline in place of the NaHS in each case served as control. Western blotting, fluorescence assay, and a mitochondrial swelling assay were employed to observe the results of caspase-3 activation, mitochondrial dysfunction, and ROS and ATP levels.

Results: NaHS significantly mitigated isoflurane-induced cognitive impairment in mice. In cultured cells, NaHS reduced caspase-3 activation, ROS, mitochondria membrane reduction, mitochondrial permeability transition pore opening, and cellular ATP level. NaHS could ameliorate cognitive impairment induced by isoflurane through inhibiting caspase-3 activation, oxidative stress, and mitochondrial dysfunction.

Conclusion: These results indicate that hydrogen sulfide (H₂S) has potential protective function against isoflurane-induced cognitive impairment. Further investigation of NaHS as an intervention to attenuate anesthesia-associated neurotoxicity is vital.

Keywords: Hydrogen sulfide, isoflurane-cognition, fear conditioning, neurotoxicity

INTRODUCTION

Alzheimer’s disease (AD) is a prevailing reason for dementia in adults [1]. Symptoms typically start at age of 60 years and might involve memory loss, failure in performing daily activities, and personality change. The evidence so far shows that exposure to general anesthetics could interact with AD-associated pathological mechanisms, and promote the progression of AD [2].
A randomized controlled trial showed that sevoflurane could accelerate the progression of cognitive impairment, which often precedes AD [3]. A case-control study in China established that anesthesia during surgery is associated with the risk of dementia [4]. Another study indicated that people in the middle age without cognitive impairment are more likely to have rapid cognitive decline after surgery and anesthesia [5]. Several other studies, however, failed to establish this association in anesthesia and dementia [6-8]. It was previously reported that isoflurane might promote caspase-3 activation [9], increase amyloid beta-protein (Aβ) level in the brain [10-12], and impair learning and memory [13]. The mechanism on how isoflurane enhances caspase activation is not completely understood, but may result from increased levels of ROS, mitochondrial dysfunction and decreased ATP level [14,15].

In addition to being a gaseous neuromodulator, H₂S is also an anti-oxidant and could produce anti-apoptotic effects in neurons and glial cells [16-23]. Accumulating evidence indicates the protective functions of H₂S in the CNS in the process of AD, vascular dementia, and Parkinson’s disease [24-27].

In this study, we hypothesized that sodium hydrosulfide (NaHS) might inhibit caspase-3 activation via ROS-, mitochondria-, and ATP-associated mechanisms in glioma cells transfected with amyloid precursor. Therefore, the purpose of this study was to explore the underlying mechanisms of caspase-3 activation in vitro and examine the potential effect of NaHS on cognitive impairment in isoflurane-induced mice model.

**EXPERIMENTAL**

**In vivo Experiments**

Following ethical approval by the Animal Care and Use Committee of Shanghai Tenth People’s Hospital, Tongji University School of Medicine, this study was carried out following the Regulations of Experimental Animal Administration. Wild-type C57BL/6J mice (8 months old) of both sexes (20 females, and 20 male, with 5 males and 5 females in each group) were placed under a reversed 12h/12h light/dark cycle at 20–22°C for a period of 1 week before the experiments in Shanghai Laboratory Animal Center, Chinese Academy of Sciences, Shanghai, China. At random, each mouse in the treatment group (10 mice; with 5 males and 5 females) received an intraperitoneal injection of 5 mg/kg NaHS (Cat #: 161527, Sigma-Aldrich, St Louis, MO, US) while each mouse in the control group (10 mice; with 5 males and 5 females) received injection of 0.1 ml saline. The dosage of NaHS used was based on previous studies, which showed that 5 mg/kg for rats would have desirable results [28-32]. Thirty minutes after NaHS or saline dose, the mice were exposed to 1.4% isoflurane in 100% O₂ for 2 hr, using a home-made chamber. Isoflurane concentration was verified, and adjusted when needed using a gas analyzer (GE Healthcare, MA, USA). All animals were consistently kept at 37 ± 0.5°C during the experiments.

Fear conditioning test was carried out as described previously [15], with slight modifications using a standard chamber from Stoelting (Wood Dale, IL, USA). On the first day after isoflurane, mice were habituated for 3 min before the presentation of the auditory tone (60 s, 3600 Hz, 80 dB). In the final 2 seconds of the tone, mice received gentle foot shock (0.8 mA, 0.5 sec) through the floor grid. After the foot shock, mice were kept in the testing chamber for 30 seconds before sending to the home cage. On the second day, mice first received a context test (without any stimulus). Two hours later, a tone test was carried out. Briefly, mice were placed in a novel context (distinct wall color and odor) for 3 min before the presentation of the tone for 3 min. During the context and tone experiments, the time during which the mice exhibited freezing behavior (failure to make any movement except respiration) was noted and evaluated with an Any-Maze video tracking system with the following settings: first, freezing on threshold for 10 sec and then freezing off threshold for 20 sec and last minimum freezing duration for mere 1 sec). The chamber was cleaned with 75% ethanol after each session.

**In vitro Experiments**

The in vitro experiments were carried out with human neuroglioma cellsH4 with transfection of human amyloid precursor protein (H4-APP cells, a gift from Dr. Zhongcong Xie at the Massachusetts General Hospital, Boston, MA, USA) [15]. Cells were maintained in high-glucose Dulbecco’s modified Eagle’s medium (Lonza, MD, USA) with 9 percent heat-inactivated fetal calf serum (Atlanta Biologicals, GA, USA), 100 μg/mL streptomycin, 2 mM L-glutamine (G1146, Sigma-Aldrich, MO, USA), 100 U/ml penicillin, and 220 μg/mL G418 (Corning Mediatech, Manassas, VA, USA) at 37 °C in humid atmosphere having 21% O₂ and 5% CO₂. Cells were treated with NaHS (final concentration: 100 μM) or vehicle in 6-well plates at 1 × 10⁶ cells in 1.5 mL as described previously, and 30 min prior
to isoflurane exposure (2%). MPTP opening, MMP, and ATP levels were examined 3 hours later; caspase-3 activation and ROS were examined 6 hours later, as detailed in previous study [15]. A Datex infrared gas analyzer was adopted to closely observe isoflurane concentration during the exposure (Puritan-Bennett, Tewksbury, MA, USA).

Western blot assay
Cells were lyyed using a buffer containing 150 mM NaCl, 10 mM Tris-HCl, 0.5% Nonidet P-40, 2 mM EDTA, 1 μg/mL leupeptin, 1 μg/mL aprotinin, and 1 μg/mL pepstatin A [15]. Lysate obtained was then centrifuged at 2500×g for 15 min and the supernatant was probed using a polyclonal rabbit-anti-mouse anti-caspase-3 antibody (Cat #: 9662, 1:1100; Cell Signaling Technology, MA, USA) that recognizes the full-length (35–40 kDa) and 17–20 kDa caspase-3. Anti-rabbit IgG (#7074, 1:5000; Cell Signal Technology) was used as secondary antibody. An enhanced chemiluminescence method (Thermo Fisher, USA) was employed and then analyzed on NIH ImageJ (US National Institutes of Health, USA). The results obtained were normalized with the β-actin control. Protein concentration was measured using a bicinchoninic method. All experiments were done six times and the mean was reported.

ROS measurement
ROS concentration was measured using OxiSelect Intracellular ROS Kit and an OxiSelect In Vitro ROS/RNS Kit (Cell Biolabs, CA, USA) as described previously [15]. The fluorescence value was maintained at 480/530 nm.

Isolation of mitochondria
Active Motif kit (Carlsbad, CA, USA) was used to isolate the mitochondria. Cell homogenate and the supernatant were centrifuged at 800 x g and 10,000 x g, at 4°C for 20 min to obtain the mitochondrial (pellet) and a cytosolic fraction ( supernatant), respectively [33].

Mitochondrial swelling
Mitochondrial swelling was examined as previously described [33,34]. The mitochondria preparation (protein concentration: 0.5 mg/ml) was placed in a buffer containing 10 mM Tris-Mops (pH 7.4), 125 mM KCl, 1 mM KH2PO4, 2.5 mM malate, 5 mM glutamate, and 10 μM EGTA-Tris (pH 7.4) for 5 min with or without adding 1 μM cyclosporine A. Time-dependent absorbance change at 540 nm in mitochondrial suspensions from isoflurane or control groups was examined using a Beckman DU 640 spectrophotometer (Beckman, CA, USA).

Evaluation of MMP
Mitochondrial membrane potential (MMP) was estimated through tetraethylbenzimidazolylcarbocyanine iodides (JC-1) fluorescence ratio detection and tetramethylrhodamine ethyl ester and perchlorate (TMRE). JC-1 MMP detection kit (30001, Biotium, CA, USA) were used as described previously [15]. MMP was calculated as the ratio of red fluorescence to green fluorescence by fluorometric plate reader (Thermo Fisher Scientific, MA, USA). For measuring MMP by TMRE, cells were treated and evaluated under a 100 X objective lens fluorescence microscope (BZ 9000, Keyence, Itasca, IL, USA).

ATP measurement
ATP (A22066 Invitrogen, CA, USA) concentration was examined as described previously [15]. Briefly, to calculate the ATP, fluorescence was measured and compared with a curve obtained from samples of known ATP.

Data analysis
Data are presented as mean values ±SD and analysed using ANOVA and post-hoc Bonferroni as appropriate. At 95% confidence interval, p<0.05 was regarded to be statistically significant.

RESULTS
NaHS ameliorates cognitive impairment induced by isoflurane
FC tests showed that mice in isoflurane group had decreased freezing time to context (Figure 1A) (F = 12.027, P < 0.0001) and to tone (Figure 1B) (F = 6.482, P = 0.004) compared to control group. Decreased freezing time suggests that the isoflurane induced the cognitive deficit. Furthermore, in the isoflurane NaHS group, the decreased freezing time was alleviated compared to isoflurane group (Figure 1A-B).

NaHS inhibits Caspase-3 activity caused by isoflurane
WB showed increased caspase-3 fragments, but not full-length caspase-3, upon isoflurane exposure (p=0.034) (Figure 2). NaHS attenuated the increase of caspase-3 fragments induced by isoflurane (p = 0.046) but did not affect caspase-
Figure 1: NaHS ameliorates isoflurane-induced cognitive impairment. 
A: Results of the FCT context test in mice treated with control conditions plus saline, isoflurane (1.4%) plus saline, control conditions plus NaHS (5 mg/kg) and isoflurane (1.4%) plus NaHS (5 mg/kg) for 2 h. B: Results of the FCT tone test in mice treated with control conditions plus saline, isoflurane (1.4%) plus saline, control conditions plus NaHS (5 mg/kg) and isoflurane (1.4%) plus NaHS (5 mg/kg). The two-way ANOVA and a post hoc Bonferroni test were used to analyze the results.

Figure 2: NaHS attenuates isoflurane-induced caspase-3 activation in H4-APP cells. 
A: Western blot showing caspase-3 activation after 6-h exposure to 2% isoflurane (lane 3) versus the control (lane 1), and the effect of 100-μM NaHS (lane 4) in H4-APP cells. GAPDH was used as a loading control. B: Statistical summary of the Western blot data. N = 6 per group. FL: full length.

3 fragment in cells not exposed to isoflurane. Isoflurane and NaHS had significant interaction (F = 5.847, p = 0.0076).

NaHS attenuates ROS increase induced by isoflurane

Isoflurane and NaHS had a significant effect on ROS level (F = 34.12, p < 0.001) (Figure 3). NaHS attenuated the increase in isoflurane-induced ROS level (p < 0.001) and decreased ROS in cells not exposed to isoflurane (p < 0.001).

NaHS attenuates isoflurane-induced mPTPs opening

Ca^{2+} induced significant mitochondria swelling in isoflurane-exposed cells (p<0.01) NaHS attenuated Ca^{2+}-induced mitochondria swelling and permeability transition (P<0.01 for isoflurane) but did not affect mitochondria swelling in cells not exposed to isoflurane (Figure 4).

Figure 3: NaHS attenuates isoflurane-induced ROS accumulation in H4-APP cells. Fluorescence staining for ROS showing the effect 6-h exposure to 2% versus the control, and the effect of 100-μM NaHS. ROS: reactive oxygen species.
NaHS attenuates isoflurane-induced MMP reduction

TMRE showed decrease in MMP in isoflurane group compared to control (Figure 5A). NaHS attenuated isoflurane-induced reduction in the MMP which was confirmed by the JC-1 fluorescence ratio (Figure 5B). Isoflurane and NaHS interacted significantly (F = 18.16, p < 0.01) (Figure 5B)

NaHS attenuates isoflurane-induced ATP reduction

A significant interaction was observed between isoflurane and NaHS (F = 7.128, p = 0.0046) (Figure 6). The post-hoc Bonferroni analysis suggested isoflurane decreased ATP (p = 0.009) inhibited by NaHS (p = 0.024).

DISCUSSION

The FCT results demonstrate that NaHS could mitigate isoflurane-induced cognitive impairment. An experiment in cultured cells showed that NaHS mitigated caspase-3 activation induced by isoflurane, ROS accumulation, ATP reduction, and mitochondrial dysfunction. This may be the first study showing NaHS could inhibit isoflurane-mediated cytotoxicity whose underlying mechanism of reduced cytotoxicity could be attributed to suppression of isoflurane-induced ROS accumulation, ATP reduction, and mitochondrial malfunction.

Oxidative stress often results in different neurodegenerative diseases. It was reported that H2S provides protection to primary neurons and immortalized mouse hippocampal cells from oxidative glutamate toxicity [19,22]. Additionally, Lu et al. discovered that H2S enhances glutamate uptake and increases glutathione.
production to prevent excessive glutamate accumulation in synaptic clefts, thus protecting astrocytes from oxidative toxicity [23]. Similarly, our findings indicate that NaHS could attenuate ROS accumulation in cells induced by isoflurane, suggesting that NaHS could mitigate the oxidative toxicity of isoflurane.

The mPTP opening decreases the potential of the membrane and releases apoptogenic proteins to amplify the apoptotic mechanism [35-38]. Oxidative and other cellular stresses cause mPTP opening [39]. In contrast, inhibition of mPTP opening protects neurons from apoptosis [34]. Hu et al. have shown that H₂S inhibits apoptosis by rotenone in SH-SY5Y cells by protecting mitochondria [21]. Xie et al. proposed that mPTP opening and MMP reduction contribute to caspase-3 activation by isoflurane, which can be attenuated by a hydrogen-rich saline [15,39]. Our findings are consistent with these findings as they show that NaHS inhibited isoflurane-induced mPTP opening, and thus attenuated caspase-3 promotion by isoflurane. These results supported the notion that caspase-3 promoted by isoflurane involved mitochondrial dysfunction and ROS mechanisms.

Our FCT experiments in mice demonstrated that NaHS could attenuate cognitive impairment caused by isoflurane exposure. This finding encourages future investigation of NaHS as a treatment for neurobehavioral decline induced by anesthesia. Various behavior studies have shown that H₂S could ameliorate cognitive and memory impairments by attenuating ROS production and the activation of apoptotic pathways. Previous studies using Morris maze test showed that H₂S (i.e., NaHS) or S-propargylcysteine (SPRC), could ameliorate lipopolysaccharide-induced cognitive impairment [28,40]. Chu et al. showed that NaHS could alleviate memory impairment in mice due to surgery [30]. A study using Aβ rat models of AD showed that NaHS could attenuate spatial memory impairment [29]. He et al. demonstrated that NaHS improved memory acquisition and spatial learning in APP/PS1 transgenic mice [25]. Altogether, these results indicated that exogenous H₂S could attenuate cognitive dysfunction due to a variety of etiological factors.

First important limitation of this study was that we did not examine the dose-response relationship as Yin et al. showed that NaHS protected from I/R injury by regulating oxidative stress in a dose-dependent manner (e.g., 0.2 and 0.4 μmol/kg) [41]. It is possible that, at different doses, NaHS may have distinct or even opposing effect on caspase-3 activity induced by isoflurane, ROS, mitochondria, and ATP. Second, the behavioral effects of NaHS were examined using only FCT. Third, we did not check the potential functions of different H₂S donors (e.g., SPRC). Effects of H₂S-releasing agents with sustained and controlled release that more faithfully mimic physiological conditions are essential. Despite these limitations, the present study showed that NaHS could attenuate cognitive impairments induced by isoflurane exposure.

CONCLUSION

This study indicated that NaHS could ameliorate isoflurane-induced cognitive impairments, likely through attenuating caspase-3 activation induced by isoflurane, mPTP opening, ROS increase, and MMP reduction. Future studies using other H₂S donors (e.g., SPRC) and other anesthetics (e.g., sevoflurane) are warranted.

DECLARATIONS

Acknowledgement

Financial support and sponsorship: this work was supported by the National Natural Science Foundation of China (81600921) to Cheng Li, Natural Science Foundation of Shanghai (16ZR1426400) to Cheng Li.

Conflict of interest

No conflict of interest is associated with this study.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. XZ and CL designed and contributed equally this work. DC, YF, LZ, XYN, XS and XZN collected data while DC wrote the manuscript which was read and approved for submission by all authors.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
REFERENCES

1. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016; 12: 459-509.

2. Bilotta F, Qева E, Matot I. Anesthesia and cognitive disorders: a systematic review of the clinical evidence. Expert Rev Neurother 2016; 16: 1311-1320.

3. Liu Y, Pan N, Ma Y, Zhang S, Guo W, Li H, Zhou J, Liu G, Gao M. Inhaled sevoflurane may promote progression of amnestic mild cognitive impairment: a prospective, randomized parallel-group study. Am J Med Sci 2013; 345: 355-360.

4. Chen GW, Lin CC, Chen KB, Kuo YC, Li CY, Chung CJ. Increased risk of dementia in people with previous exposure to general anesthesia: a nationwide population-based case-control study. Alzheimers Dement 2014; 10: 196-204.

5. Bratzke LC, Koscik RL, Schenning KJ, Clark LR, Sager MA, Johnson SC, Herrmann BP, Hogan KJ. Cognitive decline in the middle-aged after surgery and anaesthesia: results from the Wisconsin Registry for Alzheimer's Prevention cohort. Anaesthesia 2018; 73: 549-555.

6. Sprung J, Jankowski CJ, Roberts RO, Weingarten TN, Aguilar AL, Runkle KJ, Tucker AK, McLaren KC, Schroeder DR, Hanson AC, Knopman DS, Gurnier C, Warner DO. Anaesthesia and incidental dementia: a population-based, nested, case-control study. Mayo Clin Proc 2013; 88: 552-561.

7. Knopman DS, Petersen RC, Cha RH, Edland SD, Rocca WA. Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease. Neurology 2005; 65: 986-990.

8. Avidan MS, Starkebaum AC, Storandt M, Barnett K, Searleman AC, Storandt M, Barnett K, Avidan MS, Searleman AC, Storandt M, Barnett K, Avidan MS, Searleman AC, Storandt M, Barnett K. Increased risk of dementia in patients with previous exposure to general anesthesia: a nationwide population-based case-control study. Alzheimers Dement 2014; 10: 196-204.

9. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016; 12: 459-509.

10. Xie Z, Dong Y, Maeda U, Alfille P, Culley DJ, Crosby G, Tanzi RE. The common inhibition anesthetic isoflurane induces caspase activation and increases amyloid beta-protein levels. Anesthesiology 2006; 104: 988-994.

11. Xie Z, Dong Y, Maeda U, Moir RD, Xia W, Culley DJ, Crosby G, Tanzi RE. The common inhibition anesthetic isoflurane induces apoptosis and increases amyloid beta-protein levels. Anesthesiology 2006; 104: 988-994.

12. Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004; 101: 703-709.

13. Brambrink AM, Evers AS, Avidan MS, Farber NB, Smith DJ, Zhang X, Dissen GA, Creely CE, Olney JW. Isoflurane-induced neuroapoptosis in the neonatal rhesus macaque brain. Anesthesiology 2010; 112: 834-841.

14. Ni C, Li C, Dong Y, Guo X, Zhang Y, Xie Z. Anesthetic isoflurane induces DNA damage through oxidative stress and p53 pathway. Mol Neurobiol 2017; 54: 3591-3605.

15. Zhang Y, Xu Z, Wang H, Dong Y, Shi HN, Culley DJ, Crosby G, Marcantonio ER, Tanzi RE, Xie Z. Anesthetics isoflurane and desflurane differentially affect mitochondrial function, learning, and memory. Ann Neurol 2011; 71: 687-698.

16. Xie L, Yu S, Yang K, Li C, Liang Y. Hydrogen sulfide inhibits autophagic neuronal cell death by reducing oxidative stress in spinal cord ischemiareperfusion injury. Oxid Med Cell Longev 2017; 2017: 8640284.

17. Ma S, Zhong D, Ma P, Li G, Hua W, Sun Y, Liu N, Zhang L, Zhang W. Exogenoushydrogen sulfide ameliorates diabetes-associated cognitive decline by regulating the mitochondria-mediated apoptotic pathway and IL-23/IL-17 expression in db/db mice. Cell Physiol Biochem 2017; 41: 1838-1850.

18. Yu Q, Wang B, Zhao T, Zhang X, Tao L, Shi J, Sun X, Ding Q. NAlS protects against the impairments induced by oxygen-glucose deprivation in different ages of primary hippocampal neurons. Front Cell Neurosci 2017; 11: 67.

19. Kimura Y, Miruma H. Hydrogen sulfide protects neurons from oxidative stress. FASEB J 2004; 18: 1165-1167.

20. Hu X, Luan L, Guan W, Zhang S, Li B, Ji W, Fan H. Hydrogen sulfide attenuates isoflurane-induced neuroapoptosis and cognitive impairment in the developing rat brain. BMC Anesthesiol 2017; 17: 123.

21. Hu LF, Lu M, Wu ZY, Wang PT, Bian JS. Hydrogen sulfide inhibits rotenerone-induced apoptosis via preservation of mitochondrial function. Mol Pharmacol 2009; 75: 27-34.

22. Kimura Y, Dargusch R, Schubert D, Kimura H. Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. Antioxid Redox Signal 2006; 8: 661-670.

23. Lu M, Hu LF, Hu G, Bian JS. Hydrogen sulfide protects astrocytes against H(2)(O)(2)-induced neuronal injury via enhancing glutamate uptake. Free Radic Biol Med 2008; 45: 1705-1713.

24. Tang YY, Wang AP, Wei HJ, Li MH, Zou W, Li X, Wang CY, Zhang P, Tang XQ. Role of silent information regulator 1 in the protective effect of hydrogen sulfide onhomocysteine-induced cognitive dysfunction: Involving reduction of hippocampal ERstress. Behav Brain Res 2013; 248: 35-42.

25. He XL, Yan N, Zhang H, Qi WW, Zhu LJ, Liu MJ, Yan Y. Hydrogen sulfide improves spatial memory impairment and decreases production of Abeta in APP/PS1 transgenic mice. Neurochem Int 2014; 67: 1-8.

26. Sarukhani M, Haghdoost-Yazdi H, Sarbazi Golezari A, Babayan-Tazehkand A, Dargahi T, Rastgoo N. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies. Neurol Res 2015; 1-9.

27. Kumar M, Modi M, Sandhir R. Hydrogen sulfide attenuates homocysteine-induced cognitive deficits and neurochemical alterations by improving endogenous hydrosulfus levels. Biofactors 2017; 43: 434-450.

28. Gong QH, Wang Q, Pan LL, Liu XH, Huang H, Zhu YZ. Hydrogen sulfide attenuates lipopolysaccharide-induced cognitive impairment: a pro-inflammatory pathway in rats. Pharmacol Biochem Behav 2010; 96: 52-58.

29. Xuan A, Long D, Li J, Ji W, Zhang M, Hong L, Liu J. Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuroinflammation in beta-amyloid rat model of Alzheimer's disease. J Neuroinflammation 2012; 9: 202.

30. Chu QJ, He L, Zhang W, Liu CL, Ai YQ, Zhang Q. Hydrogen sulfide attenuates surgical trauma-induced inflammatory response and cognitive deficits in mice. J Surg Res 2013; 183: 330-336.

31. Fan H, Gu Y, Liang X, Yuan Y, Qi X, Wang M, Ma J, Zhou H. Hydrogen sulfide protects against amyloid beta-peptide induced neuronal injury via attenuating inflammatory responses in a rat model. J Biomed Res 2013; 27: 296-304.

32. Wang Z, Zhan J, Wang X, Gu J, Xie K, Zhang Q, Liu D. Sodium sulfide prevents hpyoxia-induced behavioral impairment in neonatal mice. Brain Res Trop J Pharm Res. April 2020; 19(4):779.
33. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat Med 2008; 14: 1097-1105.

34. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, Korsmeyer SJ. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci U S A 2005; 102: 12005-12010.

35. Halestrap A. Biochemistry: a pore way to die. Nature 2005; 434: 578-579.

36. Crompton M. Mitochondria and aging: a role for the permeability transition? Aging Cell 2004; 3: 3-6.

37. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002; 84: 153-166.

38. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434: 658-662.

39. Li C, Hou L, Chen D, Lin F, Chang T, Li M, Zhang L, Niu X, Wang H, Fu S, Zheng J. Hydrogen-rich saline attenuates isoflurane-induced caspase-3 activation and cognitive impairment via inhibition of isoflurane-induced oxidative stress, mitochondrial dysfunction, and reduction in ATP levels. Am J Transl Res 2017; 9: 1162-1172.

40. Gong QH, Wang Q, Pan LL, Liu XH, Xin H, Zhu YZ. S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: involvement of TNF signaling and NF-kappaB pathway in rats. Brain Behav Immun 2011; 25: 110-119.

41. Yin J, Tu C, Zhao J, Ou D, Chen G, Liu Y, Xiao X. Exogenous hydrogen sulfide protects against global cerebral ischemia/reperfusion injury via its antioxidative, anti-inflammatory and anti-apoptotic effects in rats. Brain Res 2013; 1491: 188-196.